Redwood City, California, Sept. 19, 2022 (The Globe Newswire) – PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, and Providence, a not-for-profit health system serving the western United States, today announced a multi-system national contract to acquire on Aqua Beam robotic systems. As of June 30, 2022, Providence had seven Aquabeam robotic systems installed throughout California and Texas.
Said Richard Shapiro, MD, FACS, on the team Providence Cedars-Sinai Tarzana Medical Center and one of the first Providence urologists to perform the new procedure. “This option appeals to men who are looking for a long-term solution with minimal risk of irreversible complications.”
“ProcePT is honored to partner with leading health systems, such as Providence, who are committed to advancing patient care through next-generation innovations, and we look forward to supporting their growing programs throughout the western United States,” said Sham Shiblak, Executive Vice President. , Commercial Director of PROCEPT. “As we continue to expand our global business footprint, our dedicated team remains focused on accelerating the adoption of Aquablation therapy and offering all patients a much-needed treatment option.”
Aquablation therapy combines real-time, multi-dimensional imaging, robotics, and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue. By combining both cystoscopy and ultrasound imaging, surgeons can create a personalized treatment plan tailored to each patient’s anatomy. Once the personalized treatment map is complete, the robotically controlled heat-free Waterjet technology ablates prostate tissue, sparing sensitive structures to preserve sexual function and urinary incontinence.1,2,3
For more information about Providence, visit www.providence.org
For more information about Aquablation Therapy, visit www.aquablation.com
Providence is a national, not-for-profit Catholic health system that includes a variety of organizations and is led by the belief that health is a human right. With 52 hospitals, more than 900 doctor’s clinics, senior services, supportive housing, and many other health and education services, the health system and its partners employ nearly 120,000 caregivers serving communities in seven states – Alaska, California, Montana , New Mexico, Oregon, Texas and Washington, and has systems offices in Renton, Washington, and Irvine, California.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on enhancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced image-guided surgical robotic system for use in minimally invasive urology with an initial focus on the treatment of benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and affects approximately 40 million men in the United States. PROCEPT Aquablation Therapy has been designed to provide effective, safe, and permanent results for males with lower urinary tract symptoms, or LUTS, due to BPH that is not dependent on the size and shape of the prostate or the surgeon’s experience. PROCEPT has developed a large and growing body of clinical evidence, which includes nine clinical studies and more than 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation Therapy.
This statement contains forward-looking statements within the meaning of the federal securities laws, including with respect to the Company’s projected financial performance for the full year 2022, and statements regarding the potential facilities, values, benefits, and advantages of Aquablation® Treatment performed with PROCEPT BioRobotics products, including AquaBeam® automated system, which involve risks and uncertainties that could cause actual results to differ materially from the expected results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are merely forecasts based on our current expectations, estimates and assumptions, are valid only as of the date they are made, and are subject to risks and uncertainties, some of which we are not currently aware of. Forward-looking statements may include statements regarding financial guidance, market and penetration opportunities, and likely or assumed future results of operations for the Company, including descriptions of the Company’s revenue, gross margin, profitability, operating expenses, demonstrated underlying growth, business momentum, and repayment coverage. , overall business strategy, and other global events on the company and its operations. Forward-looking statements should not be read as a guarantee of future performance or results, and may not necessarily be accurate indicators of when, or during which such performance or results will be achieved. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and timing of events could differ materially from those projected in such forward-looking statements as a result of these risks and uncertainties. These risks and uncertainties are fully described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s 10-K Annual Report submitted to the Securities and Exchange Commission on March 22, 2022, and in the company’s other periodic reports to the Securities and Exchange Commission. PROCEPT BioRobotics undertakes no obligation to update any forward-looking statements and expressly disclaims any obligation or undertaking to disclose publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the opinions of PROCEPT BioRobotics as of any date after the date of this press release.
Important safety information
All surgical treatments have inherent and associated side effects. For a list of possible side effects visit https://aquablation.com/safety-information/
Matt Basu, Chartered Financial Analyst
Vice President, Investor Relations and Business Operations
#Providence #Advance #Surgical #Robotics